Shanghai, August 31, 2016 – Betta Pharmaceuticals Co., Ltd. has successfully received X-396 CFDA IND approval in the class 1.1 IND application. The innovative target therapy, X-396, is aim to provide treatments for ALK positive and NSCLC patients that developed progression with crizotinib treatment. Sundia is honored to have contributed to and assisted in conducting pre-clinical CMC ( synthesis, formulation, and analysis) study as well as facilitating the successful on-site verification by the PFDA.
Home
